Navigation Links
Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc.
Date:10/9/2008

GREEN BAY, Wis., Oct. 9 /PRNewswire/ -- Nature's Way Holding Company, a subsidiary of German-based Dr. Willmar Schwabe Pharmaceuticals, a leading worldwide producer of clinically proven phytomedicines, has reached agreement to acquire all outstanding shares of Enzymatic Therapy with North Castle Partners, LLC, the controlling shareholder of Enzymatic Therapy. The agreement is subject to other shareholders delivering their signatures and provides for customary conditions to closing.

The transaction was advised by Lincoln International, a leading mid-market investment bank, who acted as the exclusive financial advisor to Schwabe and Nature's Way, working directly with the Board of Directors and senior management teams of both companies.

The combination of these organizations brings together leading industry professionals across every business discipline and creates an unsurpassed portfolio of clinically validated natural products and ingredients.

Both Nature's Way and Enzymatic Therapy, Inc. have developed a very loyal and consistently growing base of customers, consumers, and patients, who enjoy the health benefits of the products every day.

Initial focus will be to further advance product development in bringing highly effective natural health solutions to market to elevate wellness for those critical health concerns of consumers.

The group will build upon the rich heritage and advanced research and development capabilities of each of the entities to create a new standard in natural health enhancement.

Dr. Willmar Schwabe Pharmaceuticals, headquartered in Karlsruhe, Germany, was founded in 1866. Today, the group is a world-class leader in the manufacturing of herbal medicines and comprises six companies in Germany and more than 20 subsidiaries and joint ventures around the world. For more than 140 years, Schwabe Pharmaceuticals has been dedicated to providing patients and health care professionals with clinically proven herbal medicines and natural health care solutions.

As a vertically integrated pharmaceutical company, Schwabe carefully controls the manufacturing process from growing and harvesting the plants to the production of the finished goods. Schwabe products are sold in over 60 countries world-wide.

Nature's Way was founded in 1968, and has improved the life of millions of consumers by bringing the healing power of nature through herbal formulations. Nature's Way is headquartered in Springville, Utah, and its products are sold throughout leading natural products retailers throughout the United States and in 40 other countries.

Enzymatic Therapy, Inc.'s heritage is rooted in four formerly separate natural medicine companies, each of which was founded over a period from 1975 to 1986, and each of which was merged to create the company as it exists today, by North Castle Partners, LLC in 2000. Enzymatic Therapy products are sold throughout leading natural products retailers, medical clinics, and in 15 countries outside the United States.

North Castle Partners, LLC is a Private Equity Firm that invests in healthy living and healthy aging related companies, and has had a very successful track record of assisting natural products companies in creating sustainable growth platforms.

Dr. Dirk Reischig, Chairman and CEO of Schwabe: "We are very delighted that Enzymatic Therapy, Inc. joins the Schwabe group of companies. We do believe that the complementary product portfolios and marketing know-how of Enzymatic Therapy and Nature's Way will significantly strengthen our presence in the US market, which is one of Schwabe's strategic key markets for future growth. Natural health care solutions will become increasingly important over the next few decades. The joined forces of Enzymatic Therapy, Nature's Way and Schwabe will therefore contribute significantly to consumers in the USA and abroad in achieving the best possible health and quality of life."

Rory Mahony, CEO of Nature's Way: "We look forward to leveraging the knowledge and expertise resident in our companies and to further enhance the significant business growth that both Nature's Way and Enzymatic Therapy have enjoyed over the past several years. We believe the dedication of the companies to the development of quality products will benefit our customers in many ways."

Randy Rose, CEO of ETI: "We are very pleased to align with Nature's Way and Dr. Willmar Schwabe Pharmaceuticals in elevating the health and well being of consumers and patients by combining the very best know how of each of the companies. The highly ethical approach to delivering true natural medicines that improve lives is a consistent core value for all three entities and we look forward to advancing the natural health care solutions for the benefit of all."

Nature's Way Products, Inc. Enzymatic Therapy, Inc.

1375 N. Mountain Springs Parkway 825 Challenger Drive

Springville, UT 84663 Green Bay, WI 54311


'/>"/>
SOURCE Enzymatic Therapy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
3. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
4. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
5. National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Childrens Fitness
6. Hundreds of RNs from Across U.S. and World to Join California Nurses Association/NNOC National Convention
7. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
8. Depression May Be Worlds Most Disabling Disease
9. Concentra Opens On-Site Medical Unit at World Trade Center Site
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. Womens World Banking Welcomes New Network Member From Tunisia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: